2014 in review: FDA approval of new drugs

Drug Discovery Today

Volumn 22, Issue 4, 2017, Pages 620-624

  Kinch, Michael S ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTOLOZANE PLUS TAZOBACTAM; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; G PROTEIN COUPLED RECEPTOR; NEW DRUG; DRUG;

BIOTECHNOLOGY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; INFECTION; INFLUENZA; METABOLIC DISORDER; NEUROLOGIC DISEASE; SHORT SURVEY; VIRUS INFECTION; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES;

DRUG APPROVAL; HUMANS; PHARMACEUTICAL PREPARATIONS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84932111612     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.06.004     Document Type: Short Survey

References (9)

1. 1 FDA, Novel New Drugs: 2014 Summary. 2015, FDA.
2. 2 Kinch, M.S., et al. An overview of FDA-approved new molecular entities: 1827–2013. Drug Discov. Today 19 (2014), 1033–1039.
3. 3 Kinch, M.S., The rise (and decline?) of biotechnology. Drug Discov. Today 19 (2014), 1686–1690.
4. 4 Kinch, M.S., et al. Trends in pharmaceutical targeting of clinical indications: 1930–2013. Drug Discov. Today 19 (2014), 1682–2165.
5. 5 Kinch, M.S., et al. Target selection for FDA-approved medicines. Drug Discov. Today, 2014, 10.1016/j.drudis.2014.11.001 (published online 11.11.14).
6. 6 Fleming, J.J., The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation. Health Aff. 34 (2015), 271–276.
7. 7 Ford, D., Nelsen, B., The view beyond venture capital. Nat. Biotechnol. 32 (2014), 15–23.
8. 8 Pollack, A., Riding high, biotech firms remain wary. New York Times, January 15, 2015.
9. 9 Thomas, D., Wessel, C., Venture Funding of Therapeutic Innovation. 2015, Biotechnology Industry Organization.